Prices as of 2026/10/30 close
Company comparison
Medipal is the bigger company, with revenue of ¥3.8T — 9.0x Uchida Yoko's ¥425.7B.
Uchida Yoko earns more on each yen of sales, with an operating margin of 3.7% — 2.3 points above Medipal (1.4%).
Revenue growth in the latest results: Uchida Yoko +26.3%, Medipal +4.0%. For next year, Medipal guides for the fastest operating profit growth (+3.4%).
Medipal pays more on average — ¥8.14M against ¥7.78M at Uchida Yoko.
Over the past year the shares moved Medipal +37.9%, Uchida Yoko +18.4%.
Head-to-head wins14 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Medipal aheadMedipal 3 : Uchida Yoko 0
Revenue: Medipal ¥3.8T / Uchida Yoko ¥425.7B
ProfitabilityInvestors
Uchida Yoko aheadMedipal 1 : Uchida Yoko 2
Operating margin: Medipal 1.4% / Uchida Yoko 3.7%
GrowthInvestors
EvenMedipal 2 : Uchida Yoko 2
Revenue growth (YoY): Medipal +4.0% / Uchida Yoko +26.3%
Stock & balance sheetInvestors
Medipal aheadMedipal 2 : Uchida Yoko 0
Share price, 1 year: Medipal +37.9% / Uchida Yoko +18.4%
Pay & workforceJob seekers
Medipal aheadMedipal 2 : Uchida Yoko 0
Average salary: Medipal ¥8.14M / Uchida Yoko ¥7.78M
| Metric | Medipal | Uchida Yoko | Gap |
|---|---|---|---|
| Revenue | ◎¥3.8T | ¥425.7B | 9.0x |
| Operating profit | ◎¥53.2B | ¥15.6B | 3.4x |
| Net income | ◎¥42.5B | ¥12.5B | 3.4x |
| Metric | Medipal | Uchida Yoko | Gap |
|---|---|---|---|
| Operating margin | 1.4% | ◎3.7% | 2.3pt |
| Net margin | 1.1% | ◎2.9% | 1.8pt |
| ROE | — | 16.0% | |
| Revenue per employee | ◎¥20.6B | ¥383M | 53.9x |
| Metric | Medipal | Uchida Yoko | Gap |
|---|---|---|---|
| Revenue growth (YoY) | +4.0% | ◎+26.3% | 22.3pt |
| Operating profit growth (YoY) | −4.4% | ◎+28.4% | 32.8pt |
| Revenue CAGRlast 5 years | +3.5% | — | |
| Guidance: revenue growthnext FY plan | ◎+3.3% | −6.0% | 9.4pt |
| Guidance: op. profit growthnext FY plan | ◎+3.4% | −4.0% | 7.5pt |
| Metric | Medipal | Uchida Yoko | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+37.9% | +18.4% | 19.5pt |
| Share price, 3 months | ◎+14.6% | +12.0% | 2.6pt |
| P/E (trailing)lower = cheaper | — | 9.6x | |
| Equity ratio | — | 45.9% | |
| Share price (close) | ¥3,441 | ¥2,427 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Medipal | Uchida Yoko | Gap |
|---|---|---|---|
| Average salary | ◎¥8.14M | ¥7.78M | ¥0.35M |
| Starting salary (monthly) | — | ¥280,000 | |
| Average tenure | ◎19.8 yrs | 16.4 yrs | 3.4 |
| Average age | 48.6 | 40.6 | 8.0 |
| Employees | 185 | 1,113 | 6.0x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,441+37.9% (1Y)
Medipal +37.9% over 1Y. Compared: Uchida Yoko +18.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Medipal3 segments
Uchida Yoko4 segments
AAverage annual salary from the securities filings: Medipal ¥8.14M, Uchida Yoko ¥7.78M. Medipal pays the most. Averages also depend on staff age and job mix, so check the average age too (Medipal 48.6, Uchida Yoko 40.6).
ARevenue in the latest results: Medipal ¥3.8T, Uchida Yoko ¥425.7B. Medipal is the bigger company, with revenue of ¥3.8T — 9.0x Uchida Yoko's ¥425.7B.
AOperating margins: Uchida Yoko 3.7%, Medipal 1.4%. Uchida Yoko turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Medipal +37.9%, Uchida Yoko +18.4%. Medipal has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
